High levels of the pro-inflammatory molecule GM-CSF were found in the bloodstream of people with active ankylosing spondylitis (AS) and strongly correlated with disease activity, a pilot study suggested. Despite helping to lower disease activity, anti-TNF therapies did not affect GM-SCF levels. As such, GM-SCF may represent a…
Treatment with Cosentyx (secukinumab) leads to sustained reductions in symptoms of active non-radiographic axial spondyloarthritis (nr-axSpA) over one year, according to the Phase 3 PREVENT trial. These findings were the basis for Cosentyx’s recent approval…
Psoriasis in ankylosing spondylitis (AS) patients is not related to axial psoriatic arthritis (PsA), a type of psoriasis causing lower back inflammation and pain similar to AS, a new study has concluded. The results of the…
Anti-TNF therapies can halt disease progression and bone loss, and are associated with clinical improvement in people with ankylosing spondylitis after one year of treatment, a study shows. The study, “Effects of 1-year anti-TNF-α…
Get regular updates to your inbox.